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A complex interplay of intracellular signaling networks orchestrates normal cell growth
and survival, including translation, transcription, proliferation, and cell cycle progression.
Dysregulation of such signals occurs commonly in many malignancies, thereby giving
the cancer cell a survival advantage, but also providing possible targets for therapeu-
tic intervention. Activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(Akt)/mammalian target of rapamycin (mTOR) signaling pathway contributes to the prolifer-
ative advantage of malignant cells and may confer resistance to chemotherapy in various
hematologic malignancies.The initial mTOR inhibitor, sirolimus (also known as rapamycin),
was first discovered in 1975 in the soil of Easter Island. Sirolimus was originally developed
as an anti-fungal agent given its macrolide properties, but was approved by the Food and
Drug Administration (FDA) in 1999 as an immunosuppressive agent for renal transplanta-
tion patients once itsT cell suppression characteristics were recognized. Shortly thereafter,
recognition of sirolimus’s ability to inhibit cellular proliferation and cell cycle progression
brought sirolimus to the forefront as a possible inhibitor of mTOR. In the subsequent
decade, the functional roles of the mTOR protein have been more fully elucidated, and
this protein is now known to be a key regulator in a highly complex signaling pathway that
controls cell growth, proliferation, metabolism, and apoptosis. This article discusses the
dysregulation of PI3K/mTOR signaling in hematologic malignancies, including acute and
chronic leukemias, lymphomas, and lymphoproliferative disorders. The current repertoire
of PI3K/mTOR pathway inhibitors in development and clinical trials to date are described
with emphasis upon pediatric hematologic malignancies (Figure 1). Investigation of small
molecule inhibitors of this complex signaling network is an active area of oncology drug
development.
Keywords: acute lymphoblastic leukemia, acute myeloid leukemia, clinical trial, Hodgkin lymphoma, non-Hodgkin
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THE PI3K/mTOR SIGNALING NETWORK
The PI3K/mammalian target of rapamycin (mTOR) pathway is
involved in many critical cellular functions, including protein
synthesis, cell cycle progression, apoptosis, and drug resistance.
Growth factors, such as insulin-like growth factor (IGF), inter-
leukin 7 (IL-7), and fms-like tyrosine kinase 3 ligand (FLT3-L),
bind their tyrosine kinase receptors on the cell surface membrane
and induce intracellular PI3K/mTOR pathway signaling. Activa-
tion of PI3K recruits cellular protein kinases that in turn activate
downstream kinases, including the serine/threonine kinase Akt.
Phosphorylation of Akt at its threonine 308 residue inactivates the
tuberous sclerosis complexes 1 and 2 (TSC1 and TSC2), permitting
activation of the mTOR complex 1 (mTORC1) and subsequent
phosphorylation of proteins 70S6K1, S6, and the eukaryotic trans-
lation initiation factor 4E-binding protein 1 (4EBP1). This activa-
tion of mTORC1 results in increased translation and protein syn-
thesis. A second complex of mTOR, known as mTORC2, has been
more recently described and appears to act as a feedback loop via
Akt. Activation of mTORC2 via phosphorylated 70S6K1 induces
phosphorylation of Akt at its serine 473 residue, thereby inhibit-
ing mTORC1 activation and resulting in G1 cell cycle arrest and
apoptosis via 4EBP1. The tumor suppressor protein PTEN (phos-
phatase and tensin homolog deleted on chromosome 10) provides
additional negative regulation of the PI3K/mTOR pathway via
inhibition of Akt and phosphatidylinositol (3,4,5)-triphosphate
(PIP3); loss of PTEN results in upregulation of PI3K-mediated
signaling (1–5).
Oncogenesis may result from various mechanisms that dis-
rupt the PI3K/mTOR pathway. Increased surface expression of
growth factor receptors is one mechanism, such as overexpres-
sion of the IGF receptor in some leukemias (6). Mutation of
intracellular downstream effectors, including PI3K/mTOR path-
way proteins, may also result in constitutive activation of signaling.
Loss of tumor suppressors, such as PTEN, can induce dysregula-
tion of normal cellular equilibrium and thereby facilitate aberrant
signaling activation (7).
PRECLINICAL DATA IN PEDIATRIC HEMATOLOGIC
MALIGNANCIES
ACUTE LYMPHOBLASTIC LEUKEMIA
Modern genomic techniques and biochemical assays have been
used to identify upregulation of the PI3K/mTOR pathway in both
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pediatric B and T-acute lymphoblastic leukemia (ALL) (3). Var-
ious abnormalities within the PI3K/mTOR pathway have been
identified in different immunophenotypic and molecular subsets
of pediatric ALL, which may help to guide the selection of new
agents for preclinical and clinical testing. Numerous strategies
have been used to target aberrant PI3K/mTOR pathway signal-
ing in leukemias (1–3, 8, 9). To date, small molecule inhibitors
of the mTOR protein (mTOR inhibitors; MTIs) have been best
investigated in the preclinical and clinical arenas. This class of
drugs includes the first MTI, sirolimus, as well as structural deriva-
tives or analogs (“rapalogs”) such as temsirolimus, everolimus, and
ridaforolimus. Initial studies revealed that MTIs inhibit growth
and induce apoptosis in ALL cell lines and primary ALL cells
in vitro, as well as inhibit leukemia proliferation in vivo in human
ALL xenograft models (10, 11). Testing by the pediatric preclin-
ical testing program (PPTP) demonstrated significant leukemia
cytotoxicity in five of eight ALL cell lines treated with sirolimus,
particularly in T-ALL cell lines (12). In vivo testing of sirolimus
in immunocompromised murine xenograft models of pediatric
ALL through the PPTP resulted in significant survival differences
in five of eight sirolimus-treated animal models in comparison to
vehicle controls (12).
mTOR inhibitors have been found to have additive or synergis-
tic effects when combined with cytotoxic chemotherapy agents, as
well as to reverse chemotherapeutic resistance in some leukemias.
Wei et al. demonstrated resensitization of lymphoid malignancy
cells to glucocorticoid-induced apoptosis when cells were first
treated with sirolimus and that these effects were modulated at
least in part by the anti-apoptosis protein Mcl-1 (13). Further
assessment by the PPTP of combination sirolimus and dexam-
ethasone demonstrated superior in vitro cytotoxicity in six of seven
ALL cell lines and in vivo efficacy in one of three ALL xenograft
models in comparison to single-agent treatment (14). However,
combination of sirolimus with other cytotoxic agents was not addi-
tive in these studies. Teachey et al. showed that MTIs had at least
an additive or synergistic effect in vitro upon ALL cell lines when
combined with methotrexate, dexamethasone, l-asparaginase,
etoposide, or doxorubicin (15). MTIs also were found to down-
regulate cyclin D1, leading to decreased dihydrofolate reductase
(DHFR) synthesis and possibly increased sensitivity of ALL blasts
to methotrexate (15). Combination of the MTI temsirolimus with
methotrexate resulted in long-term survival of some human B-
ALL xenograft models. Crazzolara et al. noted increased survival
of B-ALL xenograft mice treated with the MTI everolimus and
vincristine in comparison to mice treated with vincristine or
everolimus alone (16). Many studies suggest that MTIs may be
more active in ALL types with worse outcomes, including T-ALL,
BCR-ABL1-rearranged, and BCR-ABL1-like (“Philadelphia-like”)
B-ALL (11, 17–20).
BCR-ABL1-POSITIVE AND BCR-ABL1-LIKE B-ALL
The BCR-ABL1 fusion protein resulting from t (9;22) activates the
PI3K/mTOR pathway directly in both chronic myeloid leukemia
(CML) and Philadelphia chromosome-positive (Ph+) ALL (17).
Although tyrosine kinase inhibitors (TKIs) targeting mutant ABL1
have revolutionized treatment of Ph+ leukemias in adults and chil-
dren, resistance mutations are a known sequelae of TKI therapy
that often result in eventual treatment failure. One study recently
demonstrated improved growth inhibition and induction of apop-
tosis when sirolimus was added to imatinib-resistant Ph+ ALL
cell lines harboring an acquired T315I resistance mutation (18).
BCR-ABL directly activates the PI3K/mTOR pathway, which may
explain some of the robust preclinical activity of MTIs in these
leukemias (17).
Recent genomic profiling efforts have identified the Philadel-
phia chromosome-like (Ph-like) subtype of B-ALL, which has a
kinase-activated gene expression profile similar to that of BCR-
ABL1-rearranged ALL and is associated with various genetic alter-
ations known or predicted to activate oncogenic cytokine receptor
signaling (21–23). Adults and children with Ph-like ALL respond
poorly to cytotoxic chemotherapy and experience high rates of
relapse. Approximately half of Ph-like ALLs harbor mutations in
Janus kinase (JAK) pathway proteins and/or rearrangements in the
cytokine receptor-like factor 2 gene (CRLF2). The CRLF2 protein
heterodimerizes with the IL-7 receptor alpha chain to form the
thymic stromal lymphopoietin receptor (TSLPR) complex. Ini-
tial studies using (non-CRLF2-rearranged) murine B-ALL models
identified activation of PI3K/mTOR signaling in these leukemias,
which was modulated by IL-7 and TSLP and could be abrogated
in vitro and in vivo by sirolimus treatment (24, 25). Subsequently,
constitutive activation of both JAK/STAT and PI3K/mTOR sig-
naling was reported specifically in in vitro analyses of primary
pediatric ALL specimens with JAK mutations and/or CRLF2
rearrangements (19). Aberrant signaling was abrogated in vitro
with co-incubation of ALL cells with TKIs, including the JAK
inhibitor ruxolitinib and various inhibitors of the PI3K/mTOR
pathway (19). The efficacy of mTOR (and JAK) inhibition has been
further studied in vivo in pediatric Ph-like ALL xenograft models.
Sirolimus treatment significantly inhibited leukemia proliferation
in eight tested models with JAK pathway mutations and/or CRLF2
rearrangements, as well as resulted in enhanced long-term animal
survival (26). Other PI3K/mTOR pathway-targeting approaches
using PI3K isoform-selective or dual protein inhibitors have also
demonstrated preliminary efficacy in vivo using these xenograft
models (20). The therapeutic potential of PI3K/mTOR inhibition
in B-ALL remains under active preclinical investigation.
T-ALL
Aberrant Notch-1 receptor signaling occurs commonly in T-
ALL, and approximately half of T-ALL patients have somatic
NOTCH1 mutations (27, 28). The intracellular Notch-1 protein,
when released after cleavage by gamma secretase, has a direct
effect on gene expression, but it has also been found to upregu-
late PI3K/mTOR pathway signaling via degradation of PTEN (27).
In T-ALL, inactivation of PTEN leads to upregulation of Akt and
mTOR, in turn leading to upregulation of cell growth and prolifer-
ation (7, 28). PTEN is inactivated through a variety of mechanisms
including mutation or deletion of PTEN itself or defects in other
signaling pathways (e.g., Ras), leading to decreased transcription
or modification of PTEN (29).
Gutierrez et al. performed array CGH and sequencing on DNA
from 44 pediatric T-ALL specimens to determine the incidence of
PI3K pathway mutations (7). They found 4 patients with PTEN
deletions, 12 cases with novel PTEN exon 7 mutations, 1 AKT
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mutation, and 4 mutations involving genes encoding PI3K pro-
teins. Alterations were mutually exclusive and in total occurred
in 47.7% (21 of 44) of pediatric T-ALL cases assessed. Correla-
tion of mutation status with clinical outcomes data revealed that
T-ALL patients with complete deletions of PTEN were far more
likely to experience induction failure (>25% residual leukemia
after 1 month of chemotherapy) than those with mutated PTEN
(7). Gain-of-function mutations in genes encoding the IL-7 recep-
tor, a previously identified MTI-sensitive target, have also been
reported in T-ALL (30, 31).
T-ALL cell lines and primary T-ALL samples with alterations in
the PI3K/mTOR pathway have been analyzed for their therapeu-
tic potential in the laboratory. MTIs as single-agents in vitro have
proven mainly cytostatic in leukemias, likely due to feedback loops
that hyperactivate Akt in response to mTORC1 downregulation.
Nonetheless, the in vivo responses to rapalogs using murine mod-
els of T-ALL seem to be superior to B-ALL. As described above,
MTIs in combination with chemotherapy or as dual PI3K path-
way protein inhibition approaches may more successfully induce
leukemia cytotoxicity and apoptosis (15, 28).
ACUTE MYELOID LEUKEMIA
Constitutive activation of PI3K/mTOR signaling occurs in the
majority of human acute myeloid leukemia (AML) and likely
results from a variety of mechanisms, including alterations in cel-
lular growth factors and mutations in FLT3, c-kit, and Ras pathway
proteins (32–34). Various MTIs appear to be cytostatic or cytotoxic
when incubated with primary AML samples in vitro and have
proven synergistic with AML-directed cytotoxic chemotherapy in
in vivo AML mouse models (35–37). Use of “next-generation”
inhibitors that more fully inhibit mTORC1 and 4EBP1 phosphory-
lation are of current interest in AML and are under active preclin-
ical investigation (2, 38). Promising preclinical data also support
use of MTIs in combination with conventional chemotherapy or
with histone deacetylase (HDAC) inhibitors, which have led to
several combination therapy clinical trials in adults (33). As afore-
mentioned, PI3K/mTOR signaling is hyperactive in CML, and
investigation of potential synergy between MTIs and TKIs tar-
geting mutant ABL1 (e.g., imatinib, dasatinib) in CML is planned
(NCT01188889) (39). Such combination approaches may be par-
ticularly useful for overcoming of TKI resistance in CML with
acquired mutations (40, 41).
MYELOPROLIFERATIVE NEOPLASMS
Many myeloproliferative neoplasms (MPNs) harbor point muta-
tions in JAK2 (Janus kinase 2) that result in signaling hyperac-
tivation involving signal transduction and activator of transcrip-
tion factors (STATs), but constitutive PI3K/mTOR activation has
also been implicated in MPNs. Everolimus was shown to inhibit
cell proliferation of JAK2 V617F mutant cell lines, and the dual
mTORC1/2 inhibitor PP242 even more potently induced apopto-
sis (42). Further, combination of the JAK1/2 inhibitor ruxolitinib
and everolimus resulted in synergistic inhibition of cell prolifera-
tion and cell cycle arrest in MPN models in vitro and in vivo (43).
NON-HODGKIN LYMPHOMA
The majority of B-cell lymphomas also have been found to have
constitutive activation of the PI3K/mTOR pathway, and MTIs
have shown anti-lymphoma activity both in vivo and in vitro
(44, 45). The mechanism by which the pathway is activated dif-
fers by lymphoma subtype. Cyclin D1 is overexpressed in man-
tle cell lymphoma, a cell cycle protein downstream of Akt and
sensitive to mTOR inhibition (44–46). PI3K appears to be con-
stitutively activated in Burkitt lymphoma cell lines (47). In a
mouse model, CMYC, a hallmark translocated gene in Burkitt
lymphomas, appears to cooperate with PI3K to create the onco-
genic phenotype (47). Co-culture of Burkitt cell lines with various
PI3K inhibitors resulted in decreased phosphorylation of Akt and
70S6K1 and subsequent cell death (48).
Abnormal activation of 70S6K1 has been described in over 90%
of adult diffuse large B-cell lymphoma (DLBCL) cases, but is less
well-defined in pediatric DLBCL (49, 50). Preclinical testing of
Burkitt lymphoma and DLBCL cell lines with MTI monotherapy
or MTIs in combination with HDAC inhibitors shows enhanced
cell apoptosis versus single-agent HDAC and substantial inhibition
of cell cycle progression, primarily due to cell cycle arrest at G0/G1
(49–51). This improved efficacy has been attributed to HDAC
inhibitors’ ability to block compensatory mTORC2-mediated Akt
upregulation that results from MTI effects upon mTORC1 (51).
Akt is frequently constitutively activated in ALCL harboring
ALK (anaplastic lymphoma kinase) mutations, and targeting with
MTIs in preclinical models has shown some activity (52).
HODGKIN LYMPHOMA
Genomic interrogation of Hodgkin lymphoma cell lines has iden-
tified dysregulation of the PI3K/mTOR pathway and high AKT
phosphorylation (53, 54). In vitro, treatment with an isoform-
selective PI3K inhibitor alone and in combination with MTIs
inhibited Hodgkin cell line proliferation (55). The combination
of the MTI everolimus and the HDAC inhibitor panobinostat has
also demonstrated synergy in induction of cell death in preclinical
testing (56).
LYMPHOPROLIFERATIVE DISORDERS
Dysregulated mTOR signaling occurs in a variety of lymphoprolif-
erative disorders, including autoimmune lymphoproliferative syn-
drome (ALPS), a disorder of lymphocyte survival due to defective
apoptosis hallmarked biologically by double negative T-cells (1).
mTOR has also been shown to be constitutively activated in post-
transplant lymphoproliferative disease (PTLD) and viral-induced
lymphoproliferative disease in children with immunodeficiencies.
First line intervention is often reduction of immunosuppression
at the cost of graft rejection, but sirolimus offers both T-cell
suppression and activity against the lymphoproliferation (57, 58).
CLINICAL TRIALS OF PI3K/mTOR PATHWAY INHIBITORS
PEDIATRIC CLINICAL TRIALS OF mTOR INHIBITORS IN HEMATOLOGIC
MALIGNANCIES
An institutional Phase 1 trial tested the safety of oral sirolimus
monotherapy in nine pediatric patients with relapsed ALL. No
dose limiting toxicity (DLT) was noted, and three ALL patients
met the criteria for stable disease (59). Based upon these data, a
subsequent single institution study is currently testing sirolimus
in combination with methotrexate in relapsed/refractory pedi-
atric ALL (NCT01162551) (39). In another institutional trial, five
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pediatric and adult patients with relapsed ALL were treated with
a combination of sirolimus and prednisone for 5 days prior to
starting multi-agent re-induction chemotherapy (60). Changes in
gene expression and protein levels, including Mcl-1, were mea-
sured in leukemia samples from these patients and compared with
samples from ALL patients treated with glucocorticoids alone. Sev-
eral patients had evidence of decreased Mcl-1 protein levels and
inhibition of phosphorylated S6 (pS6) after initiation of therapy,
suggesting successful mTOR inhibition. Among patients treated
with corticosteroids alone, most demonstrated no change in Mcl-
1 or pS6 levels. All patients treated with sirolimus and prednisone
demonstrated a decrease in circulating blasts (>80% decrease
from baseline) during the 5 days window (60). A successor trial
of oral everolimus in combination with maintenance-like ALL
therapy is currently enrolling (NCT01523977) (39).
A multi-institutional Children’s Oncology Group (COG) Phase
1 trial combined 3-weekly IV temsirolimus (10 mg/m2, de-
escalated to 7.5 mg/m2) with an intensive four drug re-induction
backbone per the UKALL R3 relapse protocol (NCT01403415)
(39, 61). Due to significant infectious toxicity, the trial was sus-
pended and recently reopened with two doses of temsirolimus
at 7.5 mg/m2. A companion trial will soon be open through the
Therapeutic Advances in Childhood Leukemia Consortium com-
bining two doses of IV temsirolimus with the standard 5 days ALL
salvage therapy of etoposide and cyclophosphamide. A single insti-
tution trial with oral sirolimus on the UKALL R3 backbone is also
currently open (NCT01658007) (39).
Sirolimus treatment has also been studied in a limited insti-
tutional series in children with ALPS. These patients have tradi-
tionally been treated with immunosuppression such as steroids
and solid organ transplant rejection/prophylaxis medications.
Five out of five patients with steroid-refractory ALPS had com-
plete responses (CRs) with resolution of lymphadenopathy with
single-agent (1). An ongoing trial for pediatric patients with
refractory ALPS has treated 12 patients to date, and 10 of these
children had CRs with resolution of lymphadenopathy and nor-
malization of blood counts (NCT00392951) (39). Eight of these
patients also eradicated their double negative T-cell population,
a hallmark of this disease (62). Children with other refractory
autoimmune-induced cytopenias (e.g., resulting from systemic
lupus erythematosus or Evans syndrome) have also experienced
clinical responses with sirolimus monotherapy (62).
ADULT CLINICAL TRIALS OF mTOR INHIBITORS IN HEMATOLOGIC
MALIGNANCIES
A Phase 1/2 study of oral everolimus in adult patients with relapsed
hematologic malignancies was recently reported (63). No DLTs
were noted, although Grade 3 toxicities occurring in more than
5% of patients included hyperglycemia (22%), hypophosphatemia
(7%), and fatigue (7%). The only published combination trial of
an MTI and high-dose chemotherapy in AML is an adult Phase
1 dose escalation trial of oral daily sirolimus on a backbone of
standard adult AML salvage therapy consisting of 5 days each of
mitoxantrone, cytarabine, and etoposide (MEC). No increased
toxicity with the MTI/chemotherapy combination occurred, and
responses (complete and partial) occurred in 22% of patients.
One patient treated at the highest dose level experienced a DLT
of prolonged marrow suppression. Overall, sirolimus was well tol-
erated and did not appear to increase non-hematologic toxicity
related to multi-agent chemotherapy (64).
A Phase 1 trial of oral everolimus in combination with cytara-
bine in elderly adults with de novo AML showed improved
median overall survival when compared to cytarabine alone (65).
Everolimus in combination with 7+ 3 cytarabine and daunomycin
in refractory/relapsed AML was fairly well tolerated and had a
CR rate of 68%, showing some improvement over historical con-
trols (66). A single-agent everolimus Phase 1/2 trial in adults with
myelofibrosis showed a 23% response rate with over 80% of the
patients experiencing symptomatic benefit (67).
Two Phase 2 studies of single-agent temsirolimus in adults
with relapsed or refractory mantle cell lymphoma have been con-
ducted to date (68, 69). In one study, objective responses were
seen in 13 of 34 patients [one CR and 12 partial responses (PRs)].
The median time-to-progression in all patients was 6.5 months,
and the median duration of response for the responders was
6.9 months (44). In the second study, 29 patients were treated and
responses were seen in 41% of patients (1 CR and 10 PRs) (45).
Phase 2 trials of single-agent everolimus in patients with refractory
Hodgkin lymphoma (HL) revealed a 42–47% overall response rate
(53). Based upon preclinical data showing synergy with combined
mTOR and HDAC targeting, a Phase 1 trial in both relapsed non-
Hodgkin lymphoma (NHL) and HL of everolimus and the HDAC
inhibitor panobinostat was performed and resulted in a similar
43% response rate in patients with HL. Some responses were also
observed in NHL patients (70).
ADULT CLINICAL TRIALS OF “NEXT-GENERATION” PI3K/mTOR
PATHWAY INHIBITORS IN HEMATOLOGIC MALIGNANCIES
Advances in structural and biochemical understanding of PI3K
enzymes have facilitated the development of new inhibitors tar-
geting other signaling proteins of the PI3K/mTOR pathway. Many
of these agents have favorable pharmacologic properties and have
proven highly efficacious in preclinical cancer studies, thus gener-
ating significant interest for clinical development of promising
inhibitors. In particular, many of these drugs are predicted or
known to induce cytotoxicity in comparison to the generally cyto-
static effects of earlier MTIs (2, 9, 71). However, the clinical efficacy
against human cancers and the side effect profiles of these drugs
upon normal tissues remain to be characterized fully (38).
Currently, six classes of PI3K/mTOR pathway inhibitors have
been developed: (a) pan-class I PI3K inhibitors, (b) isoform-
selective PI3K inhibitors, (c) Akt inhibitors, (d) MTIs/rapalogs, (e)
dual PI3K/mTOR inhibitors, and (f) TORC1/TORC2 inhibitors
(also known as TORKinibs or active-site mTOR inhibitors)
(Figure 1). All of these agents remain under active preclini-
cal study, and combination approaches of PI3K/mTOR pathway
inhibitors and other signal transduction inhibitors in hematologic
malignancies are also in progress in the laboratory (43, 72, 73).
Many of the newer non-MTI drugs have been evaluated clini-
cally in the phase 1/2 setting in adults with relapsed/refractory
solid tumors. A smaller number of mainly early phase tri-
als evaluating next-generation PI3K/mTOR pathway inhibitors
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FIGURE 1 | Schema of PI3K/mTOR and other oncogenic signaling
pathways in hematologic malignancies. Inhibitors (i) of these signaling
proteins under current preclinical or clinical study with potential therapeutic
relevance for pediatric hematologic malignancies are delineated.
Red= inhibitors of PI3K/mTOR pathway signal transduction protein(s).
in adults with relapsed/refractory hematologic malignancies are
currently open. Particular progress has been made in studying
the pan-PI3K and isoform-selective PI3K inhibitors in patients
with advanced leukemias and lymphomas, including recent FDA
approval of the PI3K p110δ isoform-selective inhibitor idelalisib
for indolent NHL (39, 71). To date, none of the next-generation
PI3K/mTOR pathway inhibitors has been evaluated specifically
in children, although preclinical studies of many of these drugs
are ongoing in childhood leukemias with the goal of swift clinical
translation (20, 74).
TOXICITY
mTOR inhibitors are generally well tolerated as single-agents
with common side effects such as hyperglycemia, hyperlipidemia,
hepatic impairment, infection, fatigue, and mucositis (44). These
toxicities have been found to be generally manageable in patients
following solid organ transplantation and in single-agent oncology
trials. Pancytopenia, most notably thrombocytopenia, has been
noted in solid tumor and NHL trials (44, 46, 51, 75). However,
MTIs have also been found to potentiate the toxicities of cytotoxic
chemotherapies, especially drugs known to cause mucositis, poor
wound healing, hypertension, and hyperglycemia (44). Although
sirolimus was not associated with increased toxicity when admin-
istered with multi-agent chemotherapy in adults with AML in
one pilot study (64), early phase clinical trial experience with tem-
sirolimus in combination with anti-ALL chemotherapy in children
resulted in unacceptable toxicity and required dose de-escalation
(SR Rheingold, personal communication 2014). Clinical evalua-
tion of next-generation PI3K/mTOR pathway inhibitors (Table 1)
remains at an early stage, but toxicities appear to be related to
immunosuppression and associated infectious sequelae, effects
upon cellular metabolism, gastrointestinal symptoms, and skin
rash (8, 38, 71). Significant toxicities may preclude further clini-
cal development of some of these next-generation inhibitors, but
efforts are ongoing to identify efficacious PI3K/mTOR pathway
inhibitors with tolerable side effect profiles (8, 38, 71). In addition,
the safety of most of these agents in children with cancer remains
to be established.
FUTURE DIRECTIONS: RATIONALLY DESIGNED
COMBINATIONS OF MULTI-PATHWAY INHIBITORS
Single-agents MTIs have shown some activity in slowing malig-
nant cell proliferation, but are unlikely to succeed as monother-
apy, as mTOR inhibition alone is often cytostatic and/or leads
to compensatory upregulation of alternate signaling pathways.
Identification of mTORC2 helped elucidate the path of compen-
satory aberrant phosphorylation noted in early MTI trials. Dual
TORC1/TORC2 inhibitors have shown some improved cytotoxic-
ity in preclinical leukemia models, but have not yet been evaluated
clinically in patients with hematologic malignancies (2). As above,
isoform-selective PI3K inhibitors and dual PI3K/mTOR inhibitors
are under early phase clinical investigation in adults with refrac-
tory cancers based upon promising preclinical data (38, 71). Akt
inhibitors under development have also shown preclinical activ-
ity in ALL with some evidence for synergy in combination with
commonly used chemotherapy agents, but have notable toxi-
city (38, 71). Table 1 lists some of the PI3K/mTOR pathway
inhibitors under evaluation in current adult clinical trials (39).
Targeting of multiple PI3K/mTOR pathway proteins may lead
to improved tumor suppression and/or decrease drug resistance,
but may also have increased cellular toxicity. Encouraging results
have also been reported in preclinical studies combining MTIs
with inhibitors of complementary signaling and protein regulation
pathways, including NOTCH, JAK/STAT, MYC, RAS, proteasomes,
and HDACs (8, 43, 51).
Compensatory signaling and feedback loops appear to dif-
fer among leukemia and lymphoma subtypes. While preclinical
results have informed the design of clinical trials to test inhibitors
of the PI3K/mTOR pathway in adults and children with hema-
tologic malignancies, significant progress remains to be made
(8, 38). Toxicity due to impaired normal protein synthesis and
cellular proliferation induced by these inhibitors must be better
understood. The results from early phase clinical trials of combi-
nation therapy are eagerly awaited. Whether classic MTIs survive
or will be surpassed by next-generation PI3K/mTOR pathway
inhibitors remains to be seen. Nonetheless, MTIs remain the far-
thest along in clinical development and have greatly expanded our
knowledge of signaling pathways essential for cell survival and
proliferation.
CONCLUSION
The identification of sirolimus in the soil of Easter Island has
led to better understanding of its critical protein target. In the
past decade, a more comprehensive description of this key sig-
naling network required for cellular proliferation and survival
has evolved. The consistent demonstration of oncogenic abnor-
malities in the PI3K/mTOR signaling pathway and in cross-talk
pathways demonstrates a clear rationale for development of sig-
nal transduction inhibitor-based approaches for children with
hematologic malignancies. Studies are ongoing to identify the
most optimal inhibitor(s) for each disease subtype. Potential
synergy with other targeted inhibitors and/or with conventional
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Table 1 | PI3K/Akt/mTOR inhibitors in clinical trials for hematologic malignancies.
Target(s) Phase of testing Clinical trial number
MTOR INHIBITORS
Sirolimus (rapamycin) mTOR FDA-approved *NCT01162551 *NCT01658007 *NCT01670175
Temsirolimus (CCI-779) mTOR FDA-approved *NCT01403415 (COG ADVL1114) *NCT01614197 (TACL 2008-004)
Everolimus (RAD001) mTOR FDA-approved *NCT01523977
Ridaforolimus (AP23573) mTOR FDA-approved completed
PI3K INHIBITORS
BKM120 Pan-PI3K (class I) Phase 1/2 NCT01396499 NCT01660451 NCT01693614 NCT01719250 NCT02049541
BAY80-6946 Pan-PI3K (class I) Phase 1/2 NCT01660451
BYL719 PI3K p110α Phase 1/2 NCT01905813
GSK2636771 PI3K p110β Phase 1/2 NCT01458067
SAR260301 PI3K p110β Phase 1 NCT01596270
Idelalisib (GS-1101, CAL-101) PI3K p110δ FDA-approved Multiple single-agent and combination trials
INCB040093 PI3K p110δ Phase 1 NCT01905813
AMG 319 PI3K p110δ Phase 1 NCT01300026
TGR 1202 PI3K p110δ Phase 1 NCT01767766
IPI-145 PI3K p110γ/δ Phase 1/2/3 NCT02004522 NCT01882803 NCT01871675 NCT01476657
PI3K/MTOR INHIBITORS
BEZ235 PI3K/mTOR Phase 1/2 NCT01756118
SAR245409 PI3K/mTOR Phase 1/2 NCT01410513 NCT01403636
GDC-0980 PI3K/mTOR Phase 1/2 NCT00854152
VS-5584 PI3K/mTOR Phase 1 NCT01991938
AKT INHIBITORS
MK-2206 Akt Phase 1/2 NCT01369849
GSK2110183 Akt Phase 1/2 NCT00881946 NCT01532700
MTORC1/MTORC2 INHIBITORS
OSI-027 TORC1/TORC2 Phase 1 NCT00698243
DS-3078a TORC1/TORC2 Phase 1 NCT01588678
CC-223 TORC1/TORC2 Phase 1 NCT01177397 NCT02031419
OTHER INHIBITORS
CC-115 dual DNA-PK/mTOR Phase 1 NCT01353625
CUDC-907 PI3K & HDAC Phase 1 NCT01742988
Akt, A serine/threonine protein kinase B; COG, Children’s Oncology Group; DNA-PK, DNA-dependent protein kinase; HDAC, histone deacetylase;
mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; TACL, Therapeutic Advances in Childhood Leukemia consortium
NCT, ClinicalTrials.gov identifier
Open pediatric trials.
chemotherapy may provide additional therapeutic options to
optimize therapeutic efficacy and to minimize toxicity.
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